{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["1(9)"],"submitter":["Moe S"],"pubmed_abstract":["<h4>Background</h4>Drug-resistant TB (DR-TB) remains a major public health threat. In 2022, Uzbekistan reported 2,117 cases of DR-TB, with 69% tested for fluoroquinolone resistance. Limited information is available on the prevalence of resistance to bedaquiline, linezolid, and fluoroquinolone, which are key components of the all-oral treatment regimen for rifampicin-resistant TB in Uzbekistan.<h4>Methods</h4>A retrospective study was conducted using extensive programmatic data from 2019 to 2023 in Uzbekistan. We assessed second-line drug-resistant TB (SLDR-TB) rates using phenotypic drug susceptibility testing (pDST). Demographic and clinical characteristics associated with SLDR-TB were analysed using multivariable logistic regression models based on the Allen-Cady approach.<h4>Results</h4"],"journal":["IJTLD open"],"pagination":["391-397"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11409172"],"repository":["biostudies-literature"],"pubmed_title":["Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan."],"pmcid":["PMC11409172"],"pubmed_authors":["Sinha A","Sitali N","Moe S","Mikhail A","Rekart ML","Gomez D","Oluya M","Kalmuratov B","Parpieva N","Bidwell G","Allamuratova S","Tigay Z","Safaev K","Azamat I","Mamitova K","Khristusev A","Gomez-Restrepo C"],"additional_accession":[]},"is_claimable":false,"name":"Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan.","description":"<h4>Background</h4>Drug-resistant TB (DR-TB) remains a major public health threat. In 2022, Uzbekistan reported 2,117 cases of DR-TB, with 69% tested for fluoroquinolone resistance. Limited information is available on the prevalence of resistance to bedaquiline, linezolid, and fluoroquinolone, which are key components of the all-oral treatment regimen for rifampicin-resistant TB in Uzbekistan.<h4>Methods</h4>A retrospective study was conducted using extensive programmatic data from 2019 to 2023 in Uzbekistan. We assessed second-line drug-resistant TB (SLDR-TB) rates using phenotypic drug susceptibility testing (pDST). Demographic and clinical characteristics associated with SLDR-TB were analysed using multivariable logistic regression models based on the Allen-Cady approach.<h4>Results</h4","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-06-16T03:13:03.941Z","creation":"2025-04-06T03:42:24.133Z"},"accession":"S-EPMC11409172","cross_references":{"pubmed":["39301133"],"doi":["10.5588/ijtldopen.24.0351"]}}